Latest & greatest articles for donepezil

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on donepezil or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on donepezil and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for donepezil

41. Donepezil slows decline in daily life activities in people with moderate to severe Alzheimer’s disease and alleviates caregiver burden Full Text available with Trip Pro

Donepezil slows decline in daily life activities in people with moderate to severe Alzheimer’s disease and alleviates caregiver burden Donepezil slows decline in daily life activities in people with moderate to severe Alzheimer’s disease and alleviates caregiver burden | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies (...) , please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Donepezil slows decline in daily life activities in people with moderate to severe Alzheimer’s disease and alleviates

2005 Evidence-Based Mental Health

42. Vitamin E and donepezil for the treatment of mild cognitive impairment. Full Text available with Trip Pro

Vitamin E and donepezil for the treatment of mild cognitive impairment. Mild cognitive impairment is a transitional state between the cognitive changes of normal aging and early Alzheimer's disease.In a double-blind study, we evaluated subjects with the amnestic subtype of mild cognitive impairment. Subjects were randomly assigned to receive 2000 IU of vitamin E daily, 10 mg of donepezil daily, or placebo for three years. The primary outcome was clinically possible or probable Alzheimer's (...) ) or the donepezil group (hazard ratio, 0.80; 95 percent confidence interval, 0.57 to 1.13; P=0.42) during the three years of treatment. Prespecified analyses of the treatment effects at 6-month intervals showed that as compared with the placebo group, the donepezil group had a reduced likelihood of progression to Alzheimer's disease during the first 12 months of the study (P=0.04), a finding supported by the secondary outcome measures. Among carriers of one or more apolipoprotein E epsilon4 alleles, the benefit

2005 NEJM Controlled trial quality: predicted high

43. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis

A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

44. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. (Abstract)

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Cholinesterase inhibitors produce small improvements in cognitive and global assessments in Alzheimer's disease. We aimed to determine whether donepezil produces worthwhile improvements in disability, dependency, behavioural and psychological symptoms, carers' psychological wellbeing, or delay in institutionalisation. If so, which patients benefit, from what dose, and for how long?565 (...) community-resident patients with mild to moderate Alzheimer's disease entered a 12-week run-in period in which they were randomly allocated donepezil (5 mg/day) or placebo. 486 who completed this period were rerandomised to either donepezil (5 or 10 mg/day) or placebo, with double-blind treatment continuing as long as judged appropriate. Primary endpoints were entry to institutional care and progression of disability, defined by loss of either two of four basic, or six of 11 instrumental, activities

2004 Lancet Controlled trial quality: predicted high

45. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. Full Text available with Trip Pro

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. Memantine is a low- to moderate-affinity, uncompetitive N-methyl-D-aspartate receptor antagonist. Controlled trials have demonstrated the safety and efficacy of memantine monotherapy for patients with moderate to severe Alzheimer disease (AD) but no controlled trials of memantine in patients receiving a cholinesterase inhibitor have been performed.To compare (...) the efficacy and safety of memantine vs placebo in patients with moderate to severe AD already receiving stable treatment with donepezil.A randomized, double-blind, placebo-controlled clinical trial of 404 patients with moderate to severe AD and Mini-Mental State Examination scores of 5 to 14, who received stable doses of donepezil, conducted at 37 US sites between June 11, 2001, and June 3, 2002. A total of 322 patients (80%) completed the trial.Participants were randomized to receive memantine (starting

2004 JAMA Controlled trial quality: predicted high

46. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 NHS Economic Evaluation Database.

47. The value of the managed entry of new drugs: a case study of donepezil

The value of the managed entry of new drugs: a case study of donepezil The value of the managed entry of new drugs: a case study of donepezil The value of the managed entry of new drugs: a case study of donepezil Payne K, Davies L M, Noyce P R, Weiss M C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology Three models to manage the entry of new drugs (in the case, donepezil) into practice were examined. In model 1, the Health Authority managed the entry of donepezil by using existing services with consultant assessment and general practitioners (GPs) taking up prescribing after 5 weeks. In model 2, the Health Authority managed the entry of donepezil by using existing services with consultant-only prescribing. In model 3, the Health

2003 NHS Economic Evaluation Database.

48. Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-Alzheimer's dementia

Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-Alzheimer's dementia Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-Alzheimer's dementia Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-Alzheimer's dementia Fajemisin B Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Fajemisin B. Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-Alzheimer's dementia. London: Bazian Ltd (Editors), Wessex Institute for Health Research and Development, University of Southampton 2002: 9 Authors' objectives This study aims to assess the effects of acetylcholinesterase inhibitors (donepezil, rivastigmine, tacrine, galantamine) on functional outcomes in people with non-Alzheimer's dementia. Authors' conclusions We found

2002 Health Technology Assessment (HTA) Database.

49. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost effectiveness

Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost effectiveness Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost effectiveness Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost effectiveness Wolfson C, Oremus M, Shukla (...) V, Momoli F, Demers L, Perrault A, Moride Y Authors' objectives To assess the efficacy and safety of donepezil and rivastigmine in the treatment of Alzheimer's disease (AD). Searching MEDLINE, HealthSTAR and PsycINFO were searched from January 1984 to May 2000; the key terms were stated. Unpublished studies and abstracts were excluded. The reference lists in identified studies were handsearched. The search was updated by searching the same databases from May 2000 to October 2001. Study selection

2002 DARE.

50. Economic evaluation of donepezil treatment for Alzheimer's disease in Japan

assessment on the reliability of the study and the conclusions drawn. Health technology The use of donepezil (Aricept) for the treatment of mild and moderate Alzheimer's disease (AD). Patients were assumed to receive donepezil at 3 mg/day for 1 week after the start of treatment and at 5 mg/day thereafter. The comparator was standard therapy. Type of intervention Secondary prevention and palliative care. Economic study type Cost-utility analysis. Study population The study population comprised patients (...) Economic evaluation of donepezil treatment for Alzheimer's disease in Japan Economic evaluation of donepezil treatment for Alzheimer's disease in Japan Economic evaluation of donepezil treatment for Alzheimer's disease in Japan Ikeda S, Yamada Y, Ikegami N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical

2002 NHS Economic Evaluation Database.

51. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimers disease: a rapid and systematic review

Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimers disease: a rapid and systematic review Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimers disease: a rapid and systematic review Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimers disease: a rapid and systematic review Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimers disease: a rapid and systematic review. Health Technology Assessment 2001; 5(1): 1-137 Authors' objectives To provide a rapid and systematic review of the clinical

2001 Health Technology Assessment (HTA) Database.

52. Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease

Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has (...) been made for the HTA database. Citation National Institute for Clinical Excellence. Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 19. 2001 Authors' objectives To provide guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease. Authors' conclusions Guidance 1.1 The three drugs donepezil, rivastigmine

2001 Health Technology Assessment (HTA) Database.

53. Clinical and cost-effectiveness of donepezil rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review

Clinical and cost-effectiveness of donepezil rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review Clinical and cost-effectiveness of donepezil rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review Clinical and cost-effectiveness of donepezil rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N Authors' objectives To provide a rapid (...) and systematic review of the clinical effectiveness and cost-effectiveness of donepezil, rivastigmine and galantamine in the symptomatic treatment of people suffering from Alzheimer's disease (AD). Searching The following databases were searched from their inception to March to July, 2000: MEDLINE, EMBASE, the Cochrane Library, DARE, NHS EED, the National Researh Register, the Science Citation Index, BIOSIS Previews, EconLit, the MRC Clinical Trials Directory, an Early Warning System database, Current

2001 DARE.

54. Donepezil for mild and moderate Alzheimer's disease. (Abstract)

in this way, but caused severe side effects. E2020 (donepezil, Aricept) is a second generation cholinesterase inhibitor and appears to be highly specific, with relatively few side effects.The objective of this review is to assess whether or not donepezil improves the well-being of patients with mild or moderate Alzheimer's disease.The Cochrane Dementia and Cognitive Impairment Group Register of Clinical Trials, was searched using the terms 'donepezil', 'E2020' and 'ARICEPT'. Medline, PsychLIT and EMBASE (...) Donepezil for mild and moderate Alzheimer's disease. Alzheimer's disease is the most common cause of dementia and is a primary degenerative disease of the brain of unknown cause. Onset is usually late in life with increasing impairment of memory, developing gradually into a global impairment of cognition, orientation, linguistic ability and judgement. The clinical course is accompanied by growing disability and dependency on care. One of the characteristic features of the disease is the widely

2000 Cochrane

55. Donepezil: a review of its use in Alzheimer's disease

Donepezil: a review of its use in Alzheimer's disease Donepezil: a review of its use in Alzheimer's disease Donepezil: a review of its use in Alzheimer's disease Dooley M, Lamb H M Authors' objectives To review the use of donepezil in Alzheimer's disease. Searching AdisBase (a proprietary database of Adis International, Auckland, New Zealand) and MEDLINE were searched from 1966 using the terms 'donepezil' or 'E-2020'. Searches were last updated 12 Jan 2000 and there were no language (...) preferred. Specific interventions included in the review Donepezil compared with placebo. In four of the included studies, patients received oral donepezil 1 to 10mg once daily for 12 to 24 weeks followed by a 2- to 6-week single-blind placebo-wash-out period. In those patients receiving 10mg per day, treatment was initiated with the 5mg dosage and increased, after one week, to 10mg. In a further three Japanese studies, two short-term trials (8 or 12 weeks duration) compared donepezil 2mg with 0.1mg

2000 DARE.

56. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease

Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease Neumann P J, Hermann R C, Kuntz K M, Araki S S, Duff S B, Leon J, Berenbaum P A, Goldman P A, Williams L W, Weinstein M C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Donepezil was compared with no pharmacological treatment for the management of mild to moderate Alzheimer's disease. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study modelled the impact of donepezil for a patient population

1999 NHS Economic Evaluation Database.

57. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada

Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada O'Brien B J, Goeree R, Hux M, Iskedjian M, Blackhouse G, Gagnon M, Gauthier S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of an anti-dementia drug, donepezil to slow the progression of dementia in patients with mild or moderate Alzheimer's Disease (AD). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Individuals with probable mild or moderate Alzheimer's Disease (Mini-Mental Health State Examination (MMSE

1999 NHS Economic Evaluation Database.

58. Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil

Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil Stewart A, Phillips R, Dempsey G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health technology studied was donepezil, a piperidine-based derivative used for the treatment of patients suffering from Alzheimer disease (AD). Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised

1998 NHS Economic Evaluation Database.

59. Donepezil in the treatment of mild to moderate senile dementia of the Alzheimer type (SDAT)

Donepezil in the treatment of mild to moderate senile dementia of the Alzheimer type (SDAT) Donepezil in the treatment of mild to moderate senile dementia of the Alzheimer type (SDAT) Donepezil in the treatment of mild to moderate senile dementia of the Alzheimer type (SDAT) Stein K Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Stein K (...) . Donepezil in the treatment of mild to moderate senile dementia of the Alzheimer type (SDAT) Southampton: Wessex Institute for Health Research and Development (WIHRD) 1997 Authors' objectives Donepezil is a new drug treatment, recently licensed in the UK, for use in mild to moderate dementia due to senile dementia of the Alzheimer type (SDAT). The author assesses whether it should be made available to all patients with mild to moderate SDAT. Authors' conclusions The effectiveness of donepezil in routine

1997 Health Technology Assessment (HTA) Database.